Zacks Research Issues Optimistic Estimate for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Research analysts at Zacks Research upped their Q1 2025 earnings per share (EPS) estimates for Allogene Therapeutics in a research note issued to investors on Wednesday, April 2nd. Zacks Research analyst R. Department now expects that the company will earn ($0.31) per share for the quarter, up from their prior forecast of ($0.37). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.26) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.40) EPS.

ALLO has been the subject of several other reports. HC Wainwright dropped their price objective on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research note on Friday, March 14th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $14.00 target price on shares of Allogene Therapeutics in a research note on Friday, March 14th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Allogene Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $9.29.

Allogene Therapeutics Stock Down 0.7 %

ALLO stock opened at $1.43 on Monday. The company has a fifty day simple moving average of $1.80 and a two-hundred day simple moving average of $2.18. The firm has a market capitalization of $310.69 million, a P/E ratio of -0.92 and a beta of 0.99. Allogene Therapeutics has a 52 week low of $1.30 and a 52 week high of $4.25.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06.

Insider Activity

In related news, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Timothy L. Moore sold 14,746 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the transaction, the insider now directly owns 250,713 shares of the company’s stock, valued at $428,719.23. This trade represents a 5.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 104,866 shares of company stock worth $194,461. 24.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Allogene Therapeutics

Hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC bought a new position in Allogene Therapeutics in the third quarter worth about $116,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Allogene Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company’s stock valued at $1,361,000 after buying an additional 5,642 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Allogene Therapeutics by 541.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 46,374 shares of the company’s stock worth $130,000 after buying an additional 39,145 shares during the last quarter. EP Wealth Advisors LLC raised its stake in shares of Allogene Therapeutics by 125.6% during the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock worth $69,000 after acquiring an additional 13,625 shares in the last quarter. Finally, Zacks Investment Management purchased a new stake in Allogene Therapeutics during the third quarter valued at approximately $1,446,000. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).